Herpes Zoster (Shingles)
The most likely cause of this patient's symptoms is herpes zoster (shingles). The clinical presentation of severe burning pain preceding a vesicular rash confined to a single dermatome is pathognomonic for varicella-zoster virus (VZV) reactivation.
Clinical Reasoning
The diagnosis is based on the classic triad that distinguishes herpes zoster from other conditions:
Dermatomal distribution: The rash overlying an entire rib on one side indicates involvement of a single thoracic dermatome, which is characteristic of VZV reactivation 1
Temporal sequence: Dermatomal pain that precedes skin findings by 24-72 hours (or sometimes longer) is highly specific for herpes zoster 1, 2, 1
Vesicular morphology: Small blisters (vesicles) on erythematous base that rapidly evolve from macules to papules to vesicles 1
Allodynia: The severe burning sensation worsened by light touch (allodynia) reflects the neuropathic nature of zoster pain
Why Not the Other Diagnoses?
Tinea corporis presents as annular, scaly plaques with central clearing—not vesicles—and lacks the severe neuropathic pain and dermatomal distribution.
Second-degree burns would require a clear history of thermal injury and would not follow dermatomal patterns or present with prodromal pain.
Mango contact allergy (urushiol dermatitis) causes linear streaks of vesicles where the allergen contacted skin, not dermatomal distribution, and lacks the characteristic burning pain that precedes the rash.
Clinical Characteristics
According to IDSA guidelines, herpes zoster typically manifests as 1:
- Unilateral vesicular eruption with dermatomal pain
- Early lesions are erythematous macules that rapidly evolve to papules then vesicles
- Vesicles frequently coalesce and form bullae before scabbing
- In healthy hosts, lesions continue to erupt for 4-6 days with total disease duration of approximately 2 weeks
- The period of contagiousness lasts until all lesions are crusted, typically 4-7 days after rash onset 3
Critical Management Points
Immediate antiviral therapy is essential to prevent complications, particularly postherpetic neuralgia. Treatment should be initiated within 72 hours of rash onset 4:
- For immunocompetent patients: Oral valacyclovir or famciclovir for 7-10 days
- For immunocompromised patients: High-dose IV acyclovir remains the treatment of choice 1
Common Pitfalls to Avoid
Don't wait for laboratory confirmation to start treatment—herpes zoster is a clinical diagnosis and antiviral therapy must begin promptly
Don't dismiss atypical presentations: Some patients present with nonspecific lesions that don't initially have the classic vesicular appearance 1
Assess immune status: While herpes zoster occurs in immunocompetent individuals, recurrent episodes or severe presentations warrant evaluation for immunosuppression 5
Monitor for dissemination: Without prompt antiviral therapy, there is a 10-20% risk of dissemination in certain populations 1